RDX013
/ Ardelyx
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
May 04, 2022
Redukx: A Study Evaluating the Safety and Efficacy of RDX013 for the Treatment of Hyperkalemia
(clinicaltrials.gov)
- P2 | N=109 | Completed | Sponsor: Ardelyx | Active, not recruiting ➔ Completed
Trial completion
January 10, 2022
Redukx: A Study Evaluating the Safety and Efficacy of RDX013 for the Treatment of Hyperkalemia
(clinicaltrials.gov)
- P2; N=120; Active, not recruiting; Sponsor: Ardelyx; Recruiting ➔ Active, not recruiting; Trial completion date: Dec 2021 ➔ Mar 2022
Clinical • Enrollment closed • Trial completion date
October 17, 2021
[VIRTUAL] RDX013, a Novel, Oral, Small Molecule Being Developed for Treatment of Hyperkalemia, Increases Colonic Secretion and Fecal Excretion of Potassium
(KIDNEY WEEK 2021)
- P2 | "Conclusion Based on its unique mechanism of action which involves pharmacologically enhancing K + secretion through apical K + channels in the colon, RDX013 is a potential first-in-class therapy which may provide a new approach to managing serum K + in patients versus commonly prescribed K + binders. A phase 2 clinical study with RDX013 (NCT04780841) is ongoing in non-dialysis CKD patients with hyperkalemia."
Atrial Fibrillation • Cardiovascular
March 04, 2021
Redukx: A Study Evaluating the Safety and Efficacy of RDX013 for the Treatment of Hyperkalemia
(clinicaltrials.gov)
- P2; N=120; Recruiting; Sponsor: Ardelyx
Clinical • New P2 trial
1 to 4
Of
4
Go to page
1